{"name":"Galvanize Therapeutics, Inc.","slug":"galvanize-therapeutics-inc","ticker":"","exchange":"","domain":"galvanize.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Nivolumab plus Platinum Doublet Chemotherapy","genericName":"Nivolumab plus Platinum Doublet Chemotherapy","slug":"nivolumab-plus-platinum-doublet-chemotherapy","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Standard of care neoadjuvant therapy","genericName":"Standard of care neoadjuvant therapy","slug":"standard-of-care-neoadjuvant-therapy","indication":"Various solid tumors as neoadjuvant pre-operative therapy (specific indication depends on cancer type and institutional standard of care)","status":"marketed"}]}],"pipeline":[{"name":"Nivolumab plus Platinum Doublet Chemotherapy","genericName":"Nivolumab plus Platinum Doublet Chemotherapy","slug":"nivolumab-plus-platinum-doublet-chemotherapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Standard of care neoadjuvant therapy","genericName":"Standard of care neoadjuvant therapy","slug":"standard-of-care-neoadjuvant-therapy","phase":"marketed","mechanism":"Standard of care neoadjuvant therapy refers to established pre-operative treatment regimens designed to shrink tumors before surgical resection.","indications":["Various solid tumors as neoadjuvant pre-operative therapy (specific indication depends on cancer type and institutional standard of care)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQbndfd05fd3h6ZjNiZDlvSUE0Zm80ZzVQcVNFSW5Vel9YNGZ4dTd1NVZsQnhLZ1BpR2g2VG14NnMyX3c0VkhDb0xkcGlPbkpaZnpTc2FEX3dzNDdrOVVsbjItSHV1aWpTNk1lbElYMFNmanplM0cyWXFCWHU4dmJ2MXdnaEVqZ3JFRlFSY1hsUXQwdVYyV2U3MFdUNy1xU1dyM1dQaWQ4Vk1lalc0Mnlnbg?oc=5","date":"2025-12-11","type":"pipeline","source":"BioPharma Dive","summary":"Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer - BioPharma Dive","headline":"Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxOOEFWMEZqOVhMajBwM25yUy13VVdaMGVDV05Jd3RIMDVYb1pKVjVsNEF2ZnJJTG11UmE4Uks3MTFFQW9BY0R2NWVOSndlZUNWVFB0eklCOG1QeDAxME1RVEJnVkNEOUFMcVdaWXdKSUdhVkxOOHgwVFpJdWhDNnFWQUMxZEpRaXM3ZGJ1SXN4WC1YOWR6eUh2M2hfT21KXzU3YVpuOU8wNjNTRkpjWVJCUXUyU0x4Qjk4WGJNTXhmQm12aFZNck0wWHdXbmM5UUFkaWZyQ0s1SHR5emJvODB0bHFEOVpwLTc5ZGJsS2RJOTlzMTkyNXotSzV6Mmk3LW4xTW51Z0pkOWF1ZndxWHBSNWNsWFBsWkd4NV85WWRCUkQ2NjJBQjIxLTlrOU54dWJzZEkzaw?oc=5","date":"2025-11-11","type":"trial","source":"PR Newswire","summary":"New Study Shows Aliya® Pulsed Electric Field Ablation Achieved Local Control of Lung Tumors in Metastatic Cancer Patients and May Induce an Immune Response - PR Newswire","headline":"New Study Shows Aliya® Pulsed Electric Field Ablation Achieved Local Control of Lung Tumors in Metastatic Cancer Patient","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBkMkdtSjE2U1YtaGlURTUtWmt3MmRUTlpWS0c4YjhrWUNJdXF2bGQ3SENESTNPSk9FTlV1YnZ4Z2RkNmhwbEtndUdqMGlJVk94Z25vVi13UjRrS2RKSTd2RU9RVy0xcXpDRWlLM2wxdk1kRmJXZm45dDNyMWtpcHc?oc=5","date":"2025-11-11","type":"pipeline","source":"MassDevice","summary":"Galvanize reports promising early results for pulsed electric field ablation for oncology - MassDevice","headline":"Galvanize reports promising early results for pulsed electric field ablation for oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQS1dOdURFRmdUa19lelBwcjNXQ2NPRnBaa2QtWGlYUlE0LUVCTkx1V0dhTnlnYVJkMjQyWFVuX3d1R0RLTHo5ZXpOYVdyMndHSV9hSnd5TDROaGFwSENISXVnUTFEcWlRQlpHV1VXWjlPMTJteHZTaUdIYlA0UXlmTlFaNTR4cU5ZQUQwSnhn?oc=5","date":"2025-09-24","type":"pipeline","source":"citybiz","summary":"Neptune Flood Could Gain $2.8B Valuation in IPO - citybiz","headline":"Neptune Flood Could Gain $2.8B Valuation in IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPUnR3VmpzX0ZtOTFhdGtfbnYyQWNFRU5sak9ydmNzU2lZSFJRVlRzN3M3Sml0dHhDcTVPODJvYnJQbTdkeUdPZXp0Mko3cjlmc18xU2lZSDVYTVIxSWtGWnRmd09fX283QjJDLXV4T3FhTVpRbGpkZDN0bk53WVJzcVNOSW1ldTZzRFJOY2kzQ3V6X3pUMzM5VWRyUV9hR2hjTmtWSzM0Ml9VSkhrUWhJcE01SlpsbzZJSnFnbw?oc=5","date":"2025-09-09","type":"regulatory","source":"MedTech Dive","summary":"Pulse wins IDE approval; Galvanize pulls in $100M - MedTech Dive","headline":"Pulse wins IDE approval; Galvanize pulls in $100M","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNV0tXWFUzSzdsckhxNjQtY2RRUnY1MVdENnRKRjZKbFhETVpwNzNSUmdPaFViTHY4NlFQQkoxM2VhbU1NX3FnUFN1U2U1b2JDVzJQQ0hDNjRZUVB2VldEYnhEMkszR0NYUGd5X1lvRHNkcVpTRkdCVF9hUVREOFJ6NnJqNHptUUhJTHBDU182MXpZN2VXYm4xbldPOG45a1VEdDh2R3AwNHlHS0JyckkzNkZqTTB2eXN3QnpDempDbw?oc=5","date":"2025-09-04","type":"pipeline","source":"Fierce Biotech","summary":"Galvanize Therapeutics nets $100M, and a new CEO, to bring pulsed field ablation to lung cancer - Fierce Biotech","headline":"Galvanize Therapeutics nets $100M, and a new CEO, to bring pulsed field ablation to lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNSzgwMGl5RXp1XzhQbThCc3BsSmFuOU40U0tSV1pTdjlHeFV1b04yZEhvalI2ZnpjVWFxN25lYXk1Rl9SeW9NS2pCOUY2MlZBWDhMZG1XcTIzVmtTalA0TWJFS09DTlY2bUQxUDlqWWI0OFRRZ0ZtbExxMDRzc0xBTzBpeFVya29nNjQ2ZmJFbXJHMGlvcGRGaEZqbE1BOWw3T1pRdUJIbXllWFViNS05bWdWdmZXNFJOSGdualpubGJmV0lZcDFkNnZYb3l3T0ktRW9YYURjY3d4ejgtaUNYUlNEVW1SZG01eEZhMGNyZkRpeFNUS0MtMnZGZzBmUjFQYVhUd2FrS21GdlBKdGRkN2RXbHFaQVBiaU1NVlNyQ0Jidw?oc=5","date":"2025-09-03","type":"pipeline","source":"PR Newswire","summary":"Galvanize Therapeutics raises $100 million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease - PR Newswire","headline":"Galvanize Therapeutics raises $100 million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQUDlyTncxRHVveGxZbnN0T1NNWXBOS3JDNGlEWVp1eWJsTXNDU0l4TTNINUpLWXFxS2RVTkdSWW15YVAtbmNiemNzUjc4aFJXR09CSjBXcXVfaGlIcjFhUEdNQ1RVVlR5Y0tjYmtEN0RaSXgzZk04LVJVZkx3OUtWTlV3?oc=5","date":"2025-09-03","type":"pipeline","source":"MassDevice","summary":"Former Shockwave CEO takes over at pulsed electric field company Galvanize Therapeutics with $100M raise - MassDevice","headline":"Former Shockwave CEO takes over at pulsed electric field company Galvanize Therapeutics with $100M raise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNYkZRMzZfX2x1azRvVlJFempzNVExSlNycXNsdTA2LUlodjV4cHY3aHBIVmxaeTBtWGRaQkYwaG4ySXpNdV9QS1p0N0RTMzJ2WDBvaGFTRzNJLXVMWHR6VExFY1U4VzR2Q0JDWGhhUmRidExsZGVhdTIwSHEwQ01QRHhzYzRGR0RfZG5Jekx6X05nbWw0eU0za1pMbFVsTkRlbG96OXhYMFl5SU9XVklzOXFnVURKa2FQTWFuSmdRU2djdw?oc=5","date":"2025-09-03","type":"pipeline","source":"Medical Product Outsourcing","summary":"Galvanize Therapeutics Hires ex-Shockwave CEO Doug Godshall as Chief Exec, Raises $100M - Medical Product Outsourcing","headline":"Galvanize Therapeutics Hires ex-Shockwave CEO Doug Godshall as Chief Exec, Raises $100M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOdjNfMVpmRFlkbDVRUllQLURsdUVZSFVjcGkzcDNBVl9LYWtBbXJvaWZqRXY2VDcxOFJjQjhKX3kzYTczdmMxUUlIZmstTnQ3S1VtSTNRMFlwaFl0cUR4ck1USlhQTjRWR29VZTJjYi0ta2pxcUdlSGtxUllyNFdwbUpvQ0x3MjJVMWhUc2szc00tUUZiX0V0SVFTUjJSUG8zRS1DbjkxaXpqZGRRMEl0TEtCS3g3SHF1UzFQQzU2UW5mdmU5c3JDRkdXTUsyQ1hoZk9jeXQ1eXotYTgxYXNlSHdxMXFVUkdOOWVQelkxa284TlpBYWxtY0hUQ3ljVUo4V2E1ajRZR1VnWHBXam93SU9PQXkzNXMxekJnMEl3?oc=5","date":"2025-08-15","type":"pipeline","source":"PR Newswire","summary":"Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya® Pulsed Electric Field Ablation for Soft Tissue Lesions - PR Newswire","headline":"Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya® Pulsed Electric Field Ablation for S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcC1mRS0ySkFKYllJUkJmOVluZ1NZY3pvY0RCYUpZeHpzajhLZjFUbFpLeEpLM0ZaLUwxMjJ5c3p4elZGSGQ4WE5NZGRwY2c2dFNielMxbnlVTUVKTC1PRS1zZHUzZS1UWGtVNFE0TE5oRGFTZGNud1ZMX2xTYkZQOWFlNG5WZlN1NG5vU2FnQXoxZTNFdm9mMW44YzNBWHZDdjdhSldoNU51XzJhYThqQUhXd0NBTXJ0enFv?oc=5","date":"2023-07-07","type":"trial","source":"Fierce Biotech","summary":"Galvanize Therapeutics lays off employees as new study of pulsed electric field tech ramps up - Fierce Biotech","headline":"Galvanize Therapeutics lays off employees as new study of pulsed electric field tech ramps up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQQzBuYnRmY2pvNTRqcjJlcXZzblhoeXlpSGJaazJZbHRwNDBFVTdGOWFwdzVycFl2QlF6ZFZZaXNpNWMtV1F6aGlLaG5remtMSHZWX3dOU0RJQWhqZ2piTFVVZGNFWHJSVmt2Szg0ZkV6dkh2T3R6MlFKaWp3XzdWbElFLUtReEFybkd5emZ1VG9jMlFmMHFlU25GYnNsbmR2SFlpamwzSi1acVpfM19scw?oc=5","date":"2022-09-15","type":"deal","source":"MassDevice","summary":"Three-way merger forms pulsed electric field therapy company Galvanize Therapeutics - MassDevice","headline":"Three-way merger forms pulsed electric field therapy company Galvanize Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}